XML 36 R22.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 28, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Takeda [Table Text Block] | Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Takeda collaboration revenues | $ | 1,940 |  |  | $ | 4,023 |  |  | $ | 6,843 |  |  | $ | 10,848 |
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Ipsen [Table Text Block] | Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Ipsen collaboration revenues | $ | 57,186 |  |  | $ | 50,679 |  |  | $ | 145,038 |  |  | $ | 60,703 |
Collaboration Revenues and Contract Assets and Liabilities | Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen in the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Royalties accruing to GSK | $ | 6,268 |  |  | $ | 3,446 |  |  | $ | 17,021 |  |  | $ | 8,809 |
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Genentech [Table Text Block] | Royalty revenues on ex-U.S. sales and our share of the profits and losses recognized in connection with COTELLIC’s commercialization in the U.S. were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2018 |  | 2017 |  | 2018 |  | 2017
Royalty revenues on ex-U.S. sales | $ | 1,390 |  |  | $ | 1,392 |  |  | $ | 4,285 |  |  | $ | 5,057 |
Profits and losses on U.S. commercialization | $ | 1,935 |  |  | $ | (891 | ) |  | $ | 6,004 |  |  | $ | (2,298 | )

X
- Definition Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - GSK [Table Text Block] + References No definition available. + Details
Name: | exel_ScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsGSKTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Genentech [Table Text Block] + References No definition available. + Details
Name: | exel_ScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsGenentechTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Ipsen [Table Text Block] + References No definition available. + Details
Name: | exel_ScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsIpsenTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions - Takeda [Table Text Block] + References No definition available. + Details
Name: | exel_ScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsTakedaTableTextBlock
Namespace Prefix: | exel_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration